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OBJECTIVE: An estimated 1.25 million Americans are chroni-
cally infected with hepatitis B virus, many of whom develop
severe and potentially fatal liver diseases. Despite the high preva-
lence and serious health consequences, little is about the impact
on quality of life of disease states resulting from chronic HBV
infection. The objective was to estimate preferences (ratings and
utility weights) for six hepatitis B-related disease states among
infected persons. METHODS: Utility weights for six disease-
related health states were elicited from a sample of 56 patients
chronically infected with HBV in San Francisco using a standard
gamble. Probability wheels with 2-color pie charts for the rela-
tive probabilities of perfect health and death were employed as
props. RESULTS: The mean age was 51y (standard deviation:
12, range: 20 to 77y) and 77% were men. Mean utilities were:
0.72 (95% conﬁdence interval: 0.68; 0.79) for chronic hepatitis
B; 0.70 (0.65; 0.77) for compensated cirrhosis; 0.42 (0.35; 0.47)
for decompensated cirrhosis; 0.48 (CI: 0.40; 0.52) for hepato-
cellular carcinoma; 0.62 (0.56; 0.67) in the ﬁrst year after liver
transplant; and 0.72 (0.65; 0.77) after ﬁrst year post-transplant.
CONCLUSION: These utility values, the ﬁrst published on
patients in the United States, indicate that health states resulting
from chronic HBV infection substantially lower patients’ quality-
of-life. These preferences (utility weights) for health states can
be incorporated into many aspects of medical decision making,
including summary measures of health related quality of life,
monitoring population health, bedside clinical decision making,
and in technology assessment. For all health states, the utilities
collected here were lower than published estimates that are based
on clinicians opinion.
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OBJECTIVE: Although the incidence of the hepatitis B virus in
the UK is low, persons with chronic infection can develop severe
and potentially fatal liver diseases. The objective was to estimate
preferences (ratings and utility weights) for six hepatitis B-related
disease states among uninfected and infected persons.
METHODS: Three hepatologists characterized the typical effects
of symptoms on health-related quality of life. Standard gamble
(SG) utility weights for six disease-related health states were
elicited from a sample of 100 uninfected persons and 87 patients
chronically infected with HBV in the UK. Probability wheels
with 2-color pie charts for the relative probabilities of perfect
health and death were used as props. RESULTS: The mean age
of patients was 43y and 46y for uninfected persons; and 57%
and 47% were men, respectively. For patients and uninfected
persons, respectively, mean SG utilities were: 0.77 (95% conﬁ-
dence interval: 0.71; 0.81) and 0.82 (0.78, 0.85); for chronic
hepatitis B; 0.73 (0.65, 0.77) and 0.83 (0.80, 0.87) for compen-
sated cirrhosis; 0.34 (0.25, 0.39) and 0.36 (0.30, 0.42) for
decompensated cirrhosis; 0.36 (0.28, 0.41) and 0.46 (0.39, 0.52)
for hepatocellular carcinoma; 0.56 (0.49, 0.62) and 0.71 (0.65,
0.76) in the ﬁrst year after liver transplant; and 0.67 (0.59, 0.73)
and 0.82 (0.78, 0.86) after ﬁrst year post-transplant. CON-
CLUSION: These utility values, the ﬁrst published on patients
or uninfected persons in the UK, indicate that health states result-
ing from chronic HBV infection substantially lower patients’
quality-of-life. The mean SG utilities were systematically lower
for infected than for uninfected persons. These preferences for
health states can be incorporated into many aspects of medical
decision making, including summary measures of health related
quality of life, monitoring population health, bedside clinical
decision making, and in technology assessment.
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OBJECTIVES: To compare the direct health costs of HIV-
positive patients reporting sub-optimal intake of antiretroviral
therapy (ART) with those of patients reporting full adherence.
METHODS: 546 subjects from the Italian multicenter observa-
tional study ICoNA (Italian Cohort Naive Antiretrovirals) were
followed between 1997 and 2004. Non-adherence to ART was
assessed by a self-administered questionnaire. Medical costs
incurred by the National Health Service were calculated retro-
spectively as from ﬁrst ART and expressed in constant 1997
prices. RESULTS: Mean time on ART was 5.75 years (range
1.04–7.77); mean HIV-RNA and CD4 cells at baseline were 4.75
log10 copies/ml (range 1.3–6.6) and 307/ml (range 0–1309). Non-
adherence was reported by 197 (36%) patients, who showed a
higher number of new AIDS-deﬁning events (p = 0.01), of
detectable viremia episodes (p < 0.001), and of ART changes 
(p = 0.01). Overall medical costs and ART costs per year were
on average €6392 (range €555–€42,183) and €5373 (range
€537–€35,582), respectively, and did not signiﬁcantly differ
between the two groups. Annual inpatient costs were higher in
the non-adherent group (€432; 95%CI €256–€608) than in the
adherent group (€198; 95%CI €127–€269; p < 0.005). On mul-
tivariate linear regression, higher HIV-RNA, lower nadir and
baseline CD4, fewer ART changes, and interaction between low
adherence and number of therapy switches were independently
associated with higher log-transformed ART costs per year.
Older age, HCV co-infection, sub-optimal ART adherence, lower
CD4 nadir, and higher baseline CD4 were independently associ-
ated with higher annual inpatient costs, based on multivariate
tobit analysis. CONCLUSIONS: Non-adherence is common
among HIV-positive patients and is associated with virological
failure, disease progression, more frequent hospitalizations 
and treatment changes. Total and ART costs do not seem to be
signiﬁcantly affected by non-adherence, probably because of
switches to simpler and less expensive treatment options,
whereas inpatient costs are signiﬁcantly increased by sub-optimal
drug intake.
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OBJECTIVE: To analyse the efﬁciency of adding Enfuvirtide
(ENF) to an Optimised Therapy (OT) in HIV patients who are
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resistant to the atirretroviral (ARV) drugs available.
METHODS: A Markov model was developed to simulate the
clinical progression of the population analyzed in the clinical
trial with a 48 weeks treatment period. A cost-effectiveness
analysis of ENF in terms of incremental cost per life year gained
(LYG) was obtained. The model was designed over a time
horizon of 10 years with monthly cycles and taking into account
the perspective of the Spanish National Health Service. The
primary clinical outcome was time until death. Efﬁcacy rates and
transition probabilities were obtained from reported clinical and
epidemiological trials. Resource use data was retrieved from
published literature in the Spanish setting and a panel of clinical
opinion leaders. Unit costs were converted to euros and adjusted
for the year 2003. RESULTS: Adding ENF to OT increases
patient’s life expectancy by 1.6 years. Total costs are €117,375
for OT and €159,121 with ENF + OT, mainly due to the fact
that increasing life expectancy for a given cohort of patients,
increases resource use and costs. Incremental cost per life year
gained with ENF is €25,687, which is similar to the value pre-
viously reported when considering results with only 24 weeks of
treatment (€24,780). CONCLUSIONS: ENF used in combina-
tion with an OT regimen increases life expectancy for HIV-1
treated patients who are highly ARV-experienced and delays
onset of new AIDS-deﬁning events, resulting in an economically
efﬁcient treatment option.
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OBJECTIVES: To estimate health care costs in ambulatory
patients living with HIV/AIDS in Spain. To identify signiﬁcative
variables associated to health care costs. METHODS: This is a
retrospective cohort study in which patients were followed up
one year, stratiﬁed by CDC-disease stage (asymptomatic-HIV,
symptomatic-HIV and AIDS). 572 patients agreed to join the
study during an outpatient visit. Data on health care services use
and costs were obtained from clinical records. Direct costs were
divided into hospitalisations, ambulatory care and drug costs.
Quality of life data from patients were obtained through EQ-5D
questionnaire. RESULTS: The mean (SD) annual health care
costs per patient in 2003 were € 8308 (4660). The main contri-
bution came from drugs (82.2% of direct costs), while hospital-
isations only represented a 4.6% of health care costs. We
identiﬁed signiﬁcative associations between health care costs
(dependent variable) and the way of contagious, the stage of
disease, health-related quality of life (HRQOL) and level of
defense in the previous year (independent variable). For instance,
a patient with a low level of defenses in the period t-1 (CD4 cell
< 200, in t-1) would have an incremental cost of 3240–4000
euros in the period t. We repeat the analysis considering phar-
maceutical costs and inpatient costs as dependent variables.
CONCLUSIONS: A high proportion of total direct costs for
people living with HIV/AIDS is due to highly active antiretrovi-
ral therapy (HAART). The current trend in Spain seems to be
shifting resources utilization from hospital admission towards
antiretroviral therapy and outpatients services. We identify sig-
niﬁcative associations between costs, clinical and HRQOL vari-
ables. This information can be useful in the development of
economic evaluation models and for the health care decisors in
the optimal allocation of resources.
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OBJECTIVES: Past studies have indicated that regimen compli-
ance is associated with virological failure which, in turn, impacts
the cost of treating HIV/AIDS. We calculated the per-patient cost
of HIV/AIDS treatment in two African countries based on
recently reported compliance studies and treatment costs.
METHODS: Patient compliance rates from recent studies in two
African countries (South Africa and Uganda) were paired with
compliance-speciﬁc virologic failure rates from the literature to
estimate the rates of treatment failure in each country. Any
patient with virologic failure was assumed to receive second-line
therapy. As a base case, we used published estimates of
HIV/AIDS annual per patient drug costs of $292 (in 2003
U.S.D.) in Uganda and $400 in South Africa for patients not
experiencing virological failure and $1594 (Uganda) and $1203
(South Africa) for patients that do experience virological failure.
The average annual per-patient drug cost was estimated for the
two countries from a non-governmental organization (NGO)
perspective. Sensitivity analyses were conducted on drug prices
and compliance rates. RESULTS: Given each country’s compli-
ance rates, the average virological failure rate was projected to
be 39% in Uganda and 68% in South Africa. The average drug
cost per patient was estimated to be $914 and $801 per year in
South Africa and Uganda, respectively. If compliance rates were
varied by +/- 25% of base case values, cost estimates ranged
from $841 to $987 for South Africa and from $756 and $935
for Uganda. Similarly, if drug costs were varied by +/- 25%, cost
estimates ranged from $685 to $1142 for South Africa and from
$601 to $1002 for Uganda. CONCLUSION: Patient compliance
is an important determinant of per-patient costs and overall
budgets for the drug cost of treating HIV/AIDS in Africa. Con-
sidering only ﬁrst and second-line unit costs does not accurately
reﬂect overall treatment costs.
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OBJECTIVES: To evaluate the psychometric properties of MINI-
HIV in HIV patients in Spanish population. METHODS: Valid-
ity, reliability and responsiveness of MINI-HIV were assessed
throughout observational, longitudinal and multicentric study
with 3 months of follow up. The 206 patients with HIV included
in the study were divided into two groups: 50 patients within the
reliability group (patients who were not foreseen any clinical
change in the following 15 days) and 156 patients within the
responsiveness group (patients that started a treatment or had a
treatment). Thus, 46 blood donor subjects were to include within
the control group. The main variable in the study was MINI-
HIV (17 items). Other variables analysed on the study were;
diagnosis date, disease symptoms, stage, previous HAART and
actual HAART, MOS-HIV and general health status. RESULTS:
The mean (SD) age of the participants was 37 (10.2), with a pre-
dominance of men (83.5 %). A total of 27.6% of the respon-
siveness group were “naïve” patients. 53.8% of the
responsiveness group and 68% reliability group patients took
only one HAART in the last year. 90% of patients answered all
questionnaire items. The mean time(SD) of questionnaire ﬁlling
by the patients was 12 (15.3) minutes. Regarding validity, MINI-
